Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

Introduction and objectives: Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence ofATTR-CA among HFpEF patients in a multicenter nationwide study. Methods: Consecutive ambulatory or h...

ver descrição completa

Detalhes bibliográficos
Autores: García-Pavía P, García-Pinilla JM, Lozano-Bahamonde A, Yun S, García-Quintana A, Gavira-Gómez JJ, Aibar-Arregui MÁ, Barge-Caballero G, Núñez Villota J, Bernal L, Tarilonte P
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p18603
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/18603
Access Level:acceso abierto
Palavra-chave:Heart failure
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Cardiac amyloidosis
Transthyretin
Transthyretin cardiac amyloidosis
id ES_b2e77d8ee7ea91b605ac0f5d6b2ffa60
oai_identifier_str oai:incliva.fundanetsuite.com:p18603
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA studyGarcía-Pavía PGarcía-Pinilla JMLozano-Bahamonde AYun SGarcía-Quintana AGavira-Gómez JJAibar-Arregui MÁBarge-Caballero GNúñez Villota JBernal LTarilonte PHeart failureLeft ventricular hypertrophyPreserved ejection fractionPrevalenceCardiac amyloidosisTransthyretinTransthyretin cardiac amyloidosisIntroduction and objectives: Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence ofATTR-CA among HFpEF patients in a multicenter nationwide study. Methods: Consecutive ambulatory or hospitalized patients aged >= 50 years with HFpEF and left ventricle hypertrophy >= 12 mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. Results: 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3 f 5.2 years, mean left ventricle ejection fraction of 60.3 f 7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II(48.4%) or III(46.8%). Besides being older than nonATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [11414796] pg/mL; P = .003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P = .085). A similar to 7% (4/56) of the patients exhibited a genetic variant (ATTRv). Conclusions: This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years. (c) 2024 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).EDICIONES DOYMA S A2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/18603REVISTA ESPANOLA DE CARDIOLOGIAISSN: 18855857ISSNl: 03008932reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAEspañolinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p186032026-06-07T16:35:31Z
dc.title.none.fl_str_mv Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
title Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
spellingShingle Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
García-Pavía P
Heart failure
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Cardiac amyloidosis
Transthyretin
Transthyretin cardiac amyloidosis
title_short Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
title_full Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
title_fullStr Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
title_full_unstemmed Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
title_sort Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
dc.creator.none.fl_str_mv García-Pavía P
García-Pinilla JM
Lozano-Bahamonde A
Yun S
García-Quintana A
Gavira-Gómez JJ
Aibar-Arregui MÁ
Barge-Caballero G
Núñez Villota J
Bernal L
Tarilonte P
author García-Pavía P
author_facet García-Pavía P
García-Pinilla JM
Lozano-Bahamonde A
Yun S
García-Quintana A
Gavira-Gómez JJ
Aibar-Arregui MÁ
Barge-Caballero G
Núñez Villota J
Bernal L
Tarilonte P
author_role author
author2 García-Pinilla JM
Lozano-Bahamonde A
Yun S
García-Quintana A
Gavira-Gómez JJ
Aibar-Arregui MÁ
Barge-Caballero G
Núñez Villota J
Bernal L
Tarilonte P
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Heart failure
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Cardiac amyloidosis
Transthyretin
Transthyretin cardiac amyloidosis
topic Heart failure
Left ventricular hypertrophy
Preserved ejection fraction
Prevalence
Cardiac amyloidosis
Transthyretin
Transthyretin cardiac amyloidosis
description Introduction and objectives: Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence ofATTR-CA among HFpEF patients in a multicenter nationwide study. Methods: Consecutive ambulatory or hospitalized patients aged >= 50 years with HFpEF and left ventricle hypertrophy >= 12 mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. Results: 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3 f 5.2 years, mean left ventricle ejection fraction of 60.3 f 7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II(48.4%) or III(46.8%). Besides being older than nonATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [11414796] pg/mL; P = .003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P = .085). A similar to 7% (4/56) of the patients exhibited a genetic variant (ATTRv). Conclusions: This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years. (c) 2024 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/18603
url https://incliva.portalinvestigacion.com/publicaciones/18603
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv EDICIONES DOYMA S A
publisher.none.fl_str_mv EDICIONES DOYMA S A
dc.source.none.fl_str_mv REVISTA ESPANOLA DE CARDIOLOGIA
ISSN: 18855857
ISSNl: 03008932
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417093913378816
score 15,811543

Registos relacionados